Matches in Wikidata for { <http://www.wikidata.org/entity/Q64140267> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q64140267 description "clinical trial" @default.
- Q64140267 description "ensayu clínicu" @default.
- Q64140267 description "klinisch onderzoek" @default.
- Q64140267 description "клінічне випробування" @default.
- Q64140267 name "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)" @default.
- Q64140267 type Item @default.
- Q64140267 label "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)" @default.
- Q64140267 prefLabel "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)" @default.
- Q64140267 P1050 Q64140267-3325C425-86B4-4EB2-884E-67BC842D3C69 @default.
- Q64140267 P1132 Q64140267-48431B20-24E7-4F06-925C-945C530C372C @default.
- Q64140267 P1476 Q64140267-29A84C92-044D-46CF-BFE9-28AE7A6AC1A0 @default.
- Q64140267 P17 Q64140267-3838F0DE-F504-46B8-A993-D2E1B8CAD840 @default.
- Q64140267 P17 Q64140267-8A07D78D-FF09-4EA9-9AF1-3A30AA805DCB @default.
- Q64140267 P17 Q64140267-9550ACE0-A643-45A1-AA0A-FE4135C0C6DB @default.
- Q64140267 P17 Q64140267-AD3BDD3E-7555-4D6B-98E2-2CDFCF934339 @default.
- Q64140267 P17 Q64140267-BD04321B-A8C2-411E-8A52-19A4030A7E1C @default.
- Q64140267 P17 Q64140267-F7A88FC5-B8D7-4D31-A3F6-E06B7B9F760A @default.
- Q64140267 P1813 Q64140267-81F73983-AD6E-4682-BB2D-603BA61CF321 @default.
- Q64140267 P2899 Q64140267-6667ACFB-E99D-4905-8CAB-17A71A638425 @default.
- Q64140267 P3098 Q64140267-76504A27-2D4A-4191-9F3E-586C0DCB59D1 @default.
- Q64140267 P31 Q64140267-B7BD8A51-B3A7-4763-A11C-FF7B8EECBAB4 @default.
- Q64140267 P4844 Q64140267-DCBB3D9C-0D69-47B9-A989-794489AB0583 @default.
- Q64140267 P580 Q64140267-6C3EE2D2-0D2D-4E33-A1D3-0C39CFD3F997 @default.
- Q64140267 P582 Q64140267-E45FD416-1664-4386-B22E-9A5459005E86 @default.
- Q64140267 P6099 Q64140267-969D20AF-DE81-42B5-8DB9-061C9932B3F7 @default.
- Q64140267 P6099 Q64140267-AA61F3A0-3F84-4248-942F-6EFB5900153D @default.
- Q64140267 P6153 Q64140267-1DAC2C70-2B3F-4655-A89E-FD022F4AFD3A @default.
- Q64140267 P6153 Q64140267-AE2360BD-B124-4693-BFDD-074C5D0C4DD7 @default.
- Q64140267 P6153 Q64140267-BC8E8C48-C255-4FDE-978C-68EE736A9371 @default.
- Q64140267 P6153 Q64140267-E622EBFF-19E3-4857-BC6C-86280E6A3D4A @default.
- Q64140267 P8363 Q64140267-3AB5E4D9-2D20-4C45-83F6-510150BA9197 @default.
- Q64140267 P1050 Q208414 @default.
- Q64140267 P1132 "+230" @default.
- Q64140267 P1476 "A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma" @default.
- Q64140267 P17 Q142 @default.
- Q64140267 P17 Q16 @default.
- Q64140267 P17 Q183 @default.
- Q64140267 P17 Q30 @default.
- Q64140267 P17 Q38 @default.
- Q64140267 P17 Q55 @default.
- Q64140267 P1813 "ROMULUS" @default.
- Q64140267 P2899 "+18" @default.
- Q64140267 P3098 "NCT01691898" @default.
- Q64140267 P31 Q30612 @default.
- Q64140267 P4844 Q412323 @default.
- Q64140267 P580 "2012-09-27T00:00:00Z" @default.
- Q64140267 P582 "2017-03-08T00:00:00Z" @default.
- Q64140267 P6099 Q42824440 @default.
- Q64140267 P6099 Q5452194 @default.
- Q64140267 P6153 Q1052562 @default.
- Q64140267 P6153 Q1452369 @default.
- Q64140267 P6153 Q2945675 @default.
- Q64140267 P6153 Q5188247 @default.
- Q64140267 P8363 Q78089383 @default.